Transforming cancer immunotherapy with affinity enhanced T-cell receptors.
Adaptimmune, a leader in T-cell therapy to treat cancer, has multiple trials ongoing in both solid tumours and hematologic cancer types, and in cancers where survival rates for patients can be very limited. Our T-cell therapies have already shown preliminary evidence of tumor reduction in patients and also show a promising risk/benefit profile.
Developed over the last 15 years, our proprietary our proprietary SPEAR® (Specific Peptide Engineered Affinity Receptor) T-cell engineering platform has generated a strong pipeline of affinity enhanced T-cell therapies. We use these therapies to harness the body’s own immune system to find and destroy diseased cells. We can develop T-cell therapies for a broad spectrum of cancer types and patients and have multiple T-cell therapies in development and/or in clinical trials.
Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality.